Статті в журналах: "Urgence nocturne"

1

Jaya Amal, Rizki. "THE IMPACT OF NOCTURIA ON MORTALITY : A SYSTEMATIC REVIEW." Journal of Advance Research in Medical & Health Science (ISSN: 2208-2425) 9, no. 4 (April 17, 2023): 17–21. http://dx.doi.org/10.53555/nnmhs.v9i4.1644.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The International Classification of Sleep Disorders (ICS) describes nocturia as "voiding that occurs during the main sleep period". However, there are some medical specialists who do not believe that feeling one emptiness while sleeping qualifies as a clinically important occurrence. They believe that this viewpoint is supported by the evidence. This might be owing to the fact that some studies have indicated that having fewer than two voids every night is not an issue, whilst other studies have found that having more than two voids every night can reduce quality of life. Having fewer than two voids every night is not a problem. Having more than two voids every night is a problem. The most common and bothersome symptom related to urination is called nocturia. 10 million people in the United States suffer with nocturia, yet only 1.5 million get treated for it. This annoys seventy percent of individuals over the age of thirty who get up at least twice throughout the night to use the toilet. People who suffer from the illness known as nocturnal enuresis are characterized by their inability to recognize when they have a full bladder and their involuntary need to empty while sleeping. Nocturia is quite similar to nocturnal frequency, with the exception that sleep comes before and after episodes of urination. Even though voiding diaries call it nocturia, getting up in the middle of the night for any reason other than to urinate is not considered to be nocturia. Convenience void. Nocturia is frequently caused by overactive bladders rather than illnesses of the urinary system. Patients who experienced urine urgency in the afternoon were also likely to have nocturia. Mortality is increased in patients with nocturia who have three or more nocturnal voids per night. The condition known as nocturia has been linked to an increased risk of death. Those who have had nocturia more than three times are at an increased risk of mortality.

2

Akashi, Shunji, and Kazue Tomita. "The impact of a history of childhood nocturnal enuresis on adult nocturia and urgency." Acta Paediatrica 103, no. 9 (August 1, 2014): e410-e415. http://dx.doi.org/10.1111/apa.12694.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Calvo Charro, María. "El derecho a un cielo oscuro. Prevención y corrección de la contaminación lumínica." Asamblea. Revista parlamentaria de la Asamblea de Madrid, no. 23 (December 1, 2010): 199–221. http://dx.doi.org/10.59991/rvam/2010/n.23/341.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

La contaminación lumínica es el resplandor producido por la luz artificial que se escapa hacia el cielo, procedente principalmente del alumbrado ineficiente, produciendo, entre otros perjuicios, aumento del gasto energético y económico, inseguridad vial, dificultades para el tráfico aéreo y marítimo, daño a los ecosistemas nocturnos y perjuicios para la salud. Es urgente proteger el cielo nocturno de la intrusión de la luz artificial, atendiendo a los beneficios que reporta para la ciencia, la cultura, la educación, el medio ambiente, la salud y la gestión responsable de los recursos energéticos. Asimismo es preciso reconocer el derecho a un cielo nocturno no contaminado que permita disfrutar de la contemplación del firmamento, como un derecho inalienable de la Humanidad, equiparable al resto de los derechos ambientales, sociales y culturales, atendiendo a su incidencia en el desarrollo de todos los pueblos y a su repercusión en la conservación de la diversidad biológica. La normativa estatal, autonómica y local, así como de las medidas administrativas capaces de incidir en la prevención y corrección de la contaminación lumínica siguen siendo hasta el momento insuficientes.

4

Fujimura, T., H. Kume, T. Sugihara, Y. Yamada, M. Suzuki, H. Nishimatsu, H. Fukuhara, T. Nakagawa, Y. Igawa, and Y. Homma. "589 Nocturia is a chaotic condition caused by nocturnal polyuria, age, comorbidity, insomnia, urgency, and bladder capacity." European Urology Supplements 13, no. 1 (April 2014): e589-e589a. http://dx.doi.org/10.1016/s1569-9056(14)60579-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Berger, Philippe. "Transfusions nocturnes de CGR sans urgence ou en urgence relative au CH de Châlons-en-Champagne : prescriptions tardives ?" Transfusion Clinique et Biologique 25, no. 4 (November 2018): 341. http://dx.doi.org/10.1016/j.tracli.2018.08.045.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Aoki*, Yoshitaka, Chieko Matsumoto, Masato Fukushima, Hideaki Ito, and Osamu Yokoyama. "MP31-15 NOCTURIA WITH OR WITHOUT URGENCY." Journal of Urology 203 (April 2020): e480-e481. http://dx.doi.org/10.1097/ju.0000000000000875.015.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Tikkinen, K. A. O., A. Auvinen, A. Tiitinen, A. Valpas, T. Keränen, A. M. Rissanen, H. Huhtala, and T. L. J. Tammela. "724 REPRODUCTIVE FACTORS ASSOCIATED WITH NOCTURIA AND URGENCY." European Urology Supplements 6, no. 2 (March 2007): 203. http://dx.doi.org/10.1016/s1569-9056(07)60719-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Mirzayeva, Nurlana, Susanne Forst, Daniel Passweg, Verena Geissbühler, Ana Paula Simões-Wüst, and Cornelia Betschart. "Bryophyllum pinnatum and Improvement of Nocturia and Sleep Quality in Women: A Multicentre, Nonrandomised Prospective Trial." Evidence-Based Complementary and Alternative Medicine 2023 (February 7, 2023): 1–8. http://dx.doi.org/10.1155/2023/2115335.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Nocturia is a pathologic condition that significantly affects the quality of sleep. The aetiology of nocturia is multifactorial, and the evidence available on its management remains limited. Besides behavioural measures, validated pharmaceutical treatment options exist but are, however, associated with marked side effects. Prospective clinical studies with tablets prepared from the leaf press juice of the plant Bryophyllum pinnatum revealed a tendency towards reduction of micturition in patients with overactive bladder (OAB) and several improvements in sleep quality. These observations are in part supported by in vitro and in vivo data. In the present study, we investigated the effectiveness of Bryophyllum 50% chewable tablets in the treatment of nocturia and associated sleep disorders. Altogether, 49 women with idiopathic OAB and nocturia of ≥2 voids/night were treated with Bryophyllum 50% tablets for 3 weeks (350 mg chewable tablets, dosage 0-0-2-2 oral tablets; WELEDA AG, Arlesheim, Switzerland). Nocturia, voiding volumes at night (ml), quality of life, sleep quality, and daily sleepiness were assessed before and after treatment with a 3-day micturition diary, the International Consultation on Incontinence evaluating overactive bladder and related impact on quality of life (QoL) [ICIQ-OAB], the Pittsburgh Sleep Quality Index (PSQI), and the Epworth Sleepiness Scale (ESS), respectively. The age of the study population was 68.5 ± 11.6 y. After treatment, nocturia diminished from 3.2 ± 1.4 to 2.3 ± 1.3 ( P < 0.001 ) and the PSQI score decreased from 7.7 ± 3.7 to 6.6 ± 3.4 ( P = 0.004 ). Urgency, the ICIQ score, and the ESS lowered significantly, and the micturition volume showed a tendency to increase. No serious adverse drug reactions were reported, and compliance was good. The results show a beneficial effect on the nocturnal voids and sleep quality of women with OAB. Bryophyllum 50% tablets can be regarded as a well-tolerated alternative in the treatment of nocturia and broaden the repertoire of standard management.

9

Garg, Ish. "A Case Study on Role of Kanchnaar Guggulu and Chandraprabhavati in the Management of Vatashtheela (BPH)." International Research Journal of Ayurveda & Yoga 05, no. 07 (2022): 112–17. http://dx.doi.org/10.47223/irjay.2022.5713.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

BenignProstaticHyperplasia(BPH)isaburningsenileproblemofelderlymen,associatedwithlowerurinarytractsymptoms(LUTS).Theprevalencefiguresvaryfromabout10-30%formenbetween50-60yearsofageto25-45%intheagegroupof70-80years.BPHisaprogressivediseasethatispresentedascommonsymptomssuchasfrequenturination,urgency,nocturia,decreasedandintermittentforceofstream,andthesensationofincompletebladderemptying.InAyurveda,VatashtheeladiseasecloselyresembleswithBenignProstaticHyperplasiaofmodernmedicineinitssignsandsymptoms.ItismanifestedduetoimproperfunctionofApanaVaatalongwiththevitiationofKaphaandPittaDoshas.Inthiscasestudy,thepatientwasadministeredChandraprabhaVati&KanchnaarGuggulu,atadoseof1tabtwiceadayand2tabtwiceadayrespectivelyfortwomonths.TheirritativeandobstructivesymptomsofBPH(Vatashtheela)likefrequency,urgency,staining,weakstream,incompleteemptying,nocturia,residualurineandsize&weightofprostatewereobservedoverthetreatment.AnalysisofresultshowedimprovementinVatashtheela(BPH).FinallystudyconcludedthatgiventreatmentisfoundeffectiveinmanagementofVatashtheela(BPH)

10

Okumura, Y., M. Fukushima, Y. Aoki, H. Ito, and O. Yokoyama. "Which affects nocturnal frequency most: Urgency or sleep disorders?" European Urology 81 (February 2022): S1242—S1243. http://dx.doi.org/10.1016/s0302-2838(22)00917-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Michel, Martin C., and Jean J. M. C. H. de la Rosette. "Role of muscarinic receptor antagonists in urgency and nocturia." BJU International 96, s1 (September 2005): 37–42. http://dx.doi.org/10.1111/j.1464-410x.2005.05651.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Akturk, Erhan, Cagdas Nurettin Emeklioglu, Hale Ozer Caltek, Necirvan Cagdas Caltek, Fatih Sahin, and Veli Mihmanli. "Urogynecological symptoms of the retroverted gravid uterus in the first half of the pregnancy: A retrospective cohort study of an underestimated, underdiagnosed and underreported issue." Journal of Surgery and Medicine 7, no. 1 (January 21, 2023): 54–57. http://dx.doi.org/10.28982/josam.7680.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Background/Aim: Urogynecological symptoms, including pelvic pain, lower backache, feeling of bearing down, frequency, nocturia, urgency, stress incontinence, and urge incontinence, are common during pregnancy. But little has been reported regarding possible changes in lower urogenital tract anatomy and its effects in pregnancy. Therefore, the subject of this study is whether the incidence of urogynecological symptoms is higher when the uterus is retroverted in pregnancy. Methods: We enrolled 1432 pregnant women examined before the 20th week of pregnancy between January 2018 and March 2022. Patients were allocated into two groups according to whether the uterus was retroverted (n=226 (15.7%)) or anteverted (n=1206 (84.3%)). These two groups were compared regarding pelvic pain, lower backache, the feeling of bearing down, frequency, nocturia, urgency, stress incontinence, and urge incontinence. Results: Retroverted gravid uterus was noted in 11.8% (n=41) of nulliparae and 17% (n=185) of multiparae (P=0.021), with an overall prevalence of 15.7%. Of 1432 patients, the overall prevalence for frequency, urgency, nocturia, urge incontinence, stress incontinence, lower backache, pelvic pain, and feeling of bearing down were 31%, 26.7%, 18.2%, 5.4%, 7.5%, 6.9%, 56.4% and 7.5%, respectively. Between both groups, there were differences in frequency, urgency, nocturia and lower back pain. There were two patients with incarcerated gravid uterus with urinary retention. Conclusion: Patients with a retroverted uterus are more likely to experience the symptoms of lower back pain, frequency, nocturia, and urgency in the first half of pregnancy.

13

Good, Larry, and Bruce P. Burnett. "Management of Loose, Frequent Stools and Fecal Incontinence in a Chronic Mesenteric Ischemia Patient with Oral Serum-derived Bovine Immunoglobulin." Clinical Medicine Insights: Gastroenterology 8 (January 2015): CGast.S21307. http://dx.doi.org/10.4137/cgast.s21307.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Aim Chronic diarrhea with fecal incontinence (FI) is a severe, underreported, and intractable problem in many patients for which limited pharmaceutical options exist. Methods A retrospective case history was collected after the administration of a prescription medical food composed of serum-derived bovine immunoglobulin/protein isolate (SBI) at 5 g once daily in a patient with chronic mesenteric ischemia (CMI) for chronic loose, frequent, and urgent stools. The patient was an 84-year-old white male with a 20-year history of progressively worsening chronic diarrhea with six to eight watery stools per day (Bristol Stool Form Scale, Type 7), urgency, nocturnal diarrhea, FI, and postprandial abdominal discomfort before administration of SBI. Results After four weeks of SBI administration, the patient had two to three soft, semi-formed stools (Bristol Stool Form Scale, Types 4 and 5) per day with no nocturnal diarrhea, urgency, or FI, as well as full resolution of abdominal discomfort. In addition, the patient expressed an enhanced quality of life (QoL): able to travel, attend social events, and perform tasks not possible before therapy. Conclusion This case underscores how a safe, nutritional therapy may offer a new modality for physicians to address chronic loose, frequent stools with FI in patients with CMI in this difficult to manage gastrointestinal population.

14

Allsworth, Jenifer E., Valerie A. Omicioli, Jacqueline A. Cunkelman, and Juell Homco. "Reproductive factors associated with nocturia and urgency: Tikkinen et al." American Journal of Obstetrics and Gynecology 199, no. 2 (August 2008): 205–6. http://dx.doi.org/10.1016/j.ajog.2008.06.037.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Jaekel, Anke K., Julius Watzek, Jörn Nielsen, Anna-Lena Butscher, Pirmin Zöhrer, Franziska Schmitz, Ruth K. M. Kirschner-Hermanns, and Stephanie C. Knüpfer. "Neurogenic Lower Urinary Tract Symptoms, Fatigue, and Depression—Are There Correlations in Persons with Multiple Sclerosis?" Biomedicines 11, no. 8 (August 4, 2023): 2193. http://dx.doi.org/10.3390/biomedicines11082193.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The symptoms of multiple sclerosis (MS) frequently include fatigue, depression, and neurogenic lower urinary tract symptoms (LUTS), causing severe burdens on affected individuals. The relationships between these symptoms have not been intensively researched and there are no studies on the detailed influence of the different neurogenic LUTS. We aimed to investigate the relationships between fatigue, depression, and neurogenic LUTS as recorded in bladder diaries by persons with MS. We analyzed the bladder diaries of 274 people and their scores on the Fatigue Scale for Motor and Cognitive Functions and the Centre for Epidemiologic Studies Depression Scale (German version). The neurogenic LUTS were defined as urgency, reduced voided volume, increased standardized voiding frequency, nocturia, and urinary incontinence. Those suffering from incontinence, nocturia, reduced voided volume, or urgency had higher fatigue scores compared to those without these symptoms. Those with nocturia showed significantly higher scores for depression. The severity of urgency and voided volume had the greatest effect on the severity of individuals’ fatigue and depression levels. With increasing urgency, the risk of clinically significant fatigue and depression was expected to increase. Urgency and voided volume correlated most with fatigue and depression. A prospective longitudinal study investigating fatigue/depression after the successful treatment of neurogenic LUTS is needed to clarify causality and offer possible treatment options for fatigue and depression.

16

Aoki, Y., C. Matsumoto, M. Fukushima, H. Ito, and O. Yokoyama. "Nocturia with or without urgency: Which is more associated with metabolic syndrome?" European Urology Open Science 19 (July 2020): e282. http://dx.doi.org/10.1016/s2666-1683(20)32742-7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Allsworth, Jenifer E., Valerie A. Omicioli, Jacqueline A. Cunkelman, and Juell Homco. "Discussion: ‘Reproductive factors associated with nocturia and urgency’ by Tikkinen et al." American Journal of Obstetrics and Gynecology 199, no. 2 (August 2008): e1-e3. http://dx.doi.org/10.1016/j.ajog.2008.06.038.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Rasool, Mumtaz, Muhammad Shahzad Saleem, Muhammad Waqas, Mudassar Saeed Pansota, and Shafqat Ali Tabassum. "LOWER URINARY TRACT SYMPTOMS." Professional Medical Journal 23, no. 11 (November 10, 2016): 1340–44. http://dx.doi.org/10.29309/tpmj/2016.23.11.1758.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Introduction: Lower urinary tract symptoms are one of the commonestpresentation in urology clinics. Lower Urinary tract symptoms include storage symptoms(frequency, urgency, urge incontinency and nocturia), voiding symptoms (hesitancy, dysuria,intermittency, poor stream of urine, terminal dribbling and residual urine sensation). Correctdetermination of prevalence of LUTS might help the health service provider to plan appropriatemanagement strategies. So this study was designed to determine frequency of LUTS in menaged 40 or above. Study Design: Descriptive, cross sectional study. Period: January 2015to December 2015. Setting: Urology Department of Bahawal Victoria Hospital, Bahawalpur.Materials & Methods: Total 228 patients of 40-80 years of age with lower urinary tract symptomswere included. Patients with foleys in situ, previously operated for urinary tract disease, urinarytract stones and urinary bladder mass were excluded. These patients were assessed todetermine frequency of lower urinary tract symptoms. Results: Mean age was 65.69 ± 7.91years. Mean duration of disease was 5.36 ± 2.19 months. Frequency of LUTS was seen in 138(60.53%) men with urgency in 22.81%, nocturia in 57.89%, frequency in 19.30%, poor streamin 15.79%, incomplete emptying of bladder in 33.33%, urge incontinence in 22.81%, terminaldribbling in 55.26% and hesitancy in 15.16% men. Conclusion: This study concluded thatthe frequency of lower urinary tract symptoms were urgency in 22.81%, nocturia in 57.89%,frequency in 19.30%, poor stream in 15.79%, incomplete emptying of bladder in 33.33%, urgeincontinence in 22.81%, terminal dribbling in 55.26% and hesitancy in 15.16% patients of age≥40 years with nocturia being the most common symptom and frequency of all symptomsincreases with age.

19

Tan, Yu Guang, Daniel Wei Keong Chan, Fabian Kok Peng Yap, and Te-Lu Yap. "Hypertensive urgency in nephrogenic diabetes insipidus with concomitant Hinman syndrome." BMJ Case Reports 12, no. 7 (July 2019): e229095. http://dx.doi.org/10.1136/bcr-2018-229095.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Diabetes insipidus is a syndrome characterised by the inability to conserve water or concentrate urine, leading to excessive excretion of urine. In congenital nephrogenic diabetes insipidus (CNDI), common presentations include failure to thrive, polydipsia, polyuria and dehydration. The long trajectory of the disease, coupled with psycho-behavioural changes as a child grows, can precipitate a period of non-adherence despite initial optimal control, especially in the adolescent age group. Social inconvenience of repeated voiding and nocturnal disturbances can lead to adapted urine holding behaviour, also known as non-neurogenic neurogenic bladder (Hinman syndrome). Anatomical changes in the urinary system, such as bladder trabeculation and hydroureteronephrosis, can subsequently give rise to functional renal impairment. We present a case of CNDI with concomitant Hinman syndrome, resulting in acute renal impairment and hypertensive emergency. We aim to raise awareness of the association between these two entities.

20

Swatesutipun, Valeerat, and Teerayut Tangpaitoon. "The Prevalence and Risk Factors of Storage Urinary Symptoms in Symptomatic COVID-19 Patients Who were Treated in Cohort Ward and Field Hospital." Siriraj Medical Journal 74, no. 2 (February 1, 2022): 134–41. http://dx.doi.org/10.33192/smj.2022.17.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Objective: The primary aim of this study was to focus on the prevalence of storage symptoms in COVID-19 patients and the factors associated with those symptoms.Material and Methods: We collected the data of COVID-19 patients who were admitted to the cohort ward, ICU and field hospital of Thammasat University Hospital, Thailand, between May and June 2021. Patients answered online survey questions and undertook urinalysis by urine dipstick test. The online survey questions related to symptoms of COVID-19 infection, number of daytime voiding, nocturia, frequency and urgency symptom during COVID-19 infection, OABSS and ICIQ-LUTS in the part of storage symptoms subscale.Results: There were 136 COVID-19 patients who met with the eligible criteria and were willing to participate in the study. Patients who had storage symptoms totaled 61 (44.85%) and had average daytime frequency, nocturia and proportion of urgency higher than no storage symptom group (5.9 VS 3.8, 2.0 VS 1.0 and 67.21% VS 6.67% (p-value <0.001), respectively). The OABSS and ICIQ storage subscale in the storage symptoms group were higher than normal group, 3.2 VS 0.9 and 4.5 VS 1.7 (p-value < 0.001), respectively.Conclusion: Our study demonstrated that the SARS-CoV-2 virus infection is associated with abnormal storagesymptoms which include frequency, urgency and nocturia. The storage symptoms may be associated with theseverity of COVID-19 disease.

21

Subhan, Sana, Syed Imran Ahmad, Muhammad Hammad Ali Mithani, Aftab Ahmed Mirza Baig, Muhammad Kashif, and Muhammad Arif Siddiqui. "Effects of transcutaneous tibial nerve stimulation for overactive bladder symptoms in adults: A randomized controlled trial." Rehabilitation Journal 07, no. 03 (September 30, 2023): 36–41. http://dx.doi.org/10.52567/trehabj.v7i03.7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Background: Overactive bladder (OAB) is characterized by urinary urgency, frequency, and nocturia, often accompanied by urinary incontinence. OAB significantly impacts the quality of life of affected individuals. Transcutaneous Tibial Nerve Stimulation (TTNS) is a non-invasive treatment option used to manage overactive bladder (OAB) symptoms. Objective: to determine the effects of Transcutaneous Tibial Nerve Stimulation on overactive bladder symptoms in adults. Methods: A randomized controlled trial was held at the Sindh Institute of Physical Medicine and Rehabilitation with a non-probability purposive sampling technique. After screening for inclusion criteria 60 patients were randomly allocated into two Group A received Transcutaneous tibial nerve stimulation (TTNS) combined with traditional physiotherapy, while Group B just received traditional physiotherapy. Both interventions were given for six weeks. The overactive Bladder Symptom Score was used as an outcome measure tool. Results: Group A improved in all OAB parameters, including daytime frequency (p=0.008), nocturia (p=0.006), urinary urgency (p=0.002), and urge urinary incontinence (p=0.008) with a significant improvement p<0.05. All OABSS parameters in group B also showed a considerable improvement (p<0.05), except for urge urinary incontinence (p=0.08). Conclusion: the daytime frequency, nocturia, and urgency parameters of the overactive bladder symptoms score significantly decreased in both the TTNS+PFM group and the Traditional physiotherapy group. However, urge urinary incontinence showed significant improvement only in the TTNS+PFM group.

22

Burns, P. A. "A nurse led continence service reduced symptoms of incontinence, frequency, urgency, and nocturia." Evidence-Based Nursing 9, no. 3 (July 1, 2006): 85. http://dx.doi.org/10.1136/ebn.9.3.85.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Minassian, Vatche, Walter Stewart, Annemarie Hirsch, Ken Kolodner, Mary Fitzgerald, Kathryn Burgio, Geoffrey Cundiff, Jerry Blaivas, Diane Newman, and Anne Dilley. "The role of urgency, frequency, and nocturia in defining overactive bladder adaptive behavior." Neurourology and Urodynamics 30, no. 3 (November 11, 2010): 406–11. http://dx.doi.org/10.1002/nau.20925.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Lin, Kun-Ling, Ching-Ju Shen, Ming-Ping Wu, Cheng-Yu Long, Chin-Hu Wu, and Chiu-Lin Wang. "Comparison of Low Urinary Tract Symptoms during Pregnancy between Primiparous and Multiparous Women." BioMed Research International 2014 (2014): 1–5. http://dx.doi.org/10.1155/2014/303697.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Background and Purpose.Low urinary tract symptoms (LUTS) are a common problem during pregnancy. This study aimed to compare changes in the prevalence of LUTS during pregnancy between primiparous and multiparous women.Methods. A chart review of consecutive pregnant women who attended our antenatal clinic from March 2002 to January 2006 was performed. All of the women were asked to respond to a LUTS questionnaire in either of the three trimesters.Results.Of the 270 women included, 164 were nullipara and 106 were multipara. The most common LUTS during pregnancy were frequency (77%), followed by nocturia (75.6%), stress urinary incontinence (SUI) (51.1%), incomplete emptying (43.7%), dysuria (17.8%), and urgency incontinence (10.4%). There was a significantly higher prevalence of SUI (P<0.001) and urgency incontinence (P=0.005) in the multiparous compared to the nulliparous women. Increasing prevalence rates of frequency, nocturia, SUI, and incomplete emptying were reported with gestational age in both the nulliparous and multiparous women.Conclusions. Frequency and nocturia were the two most common LUTS during pregnancy. The prevalence rates of all LUTS increased with increasing gestational age except for frequency in the nulliparous women during the second trimester. In addition, multipara was a predictor of SUI during pregnancy.

25

Mansfield, Kylie J. "Muscarinic Receptor Antagonists, the Overactive Bladder and Efficacy against Urinary Urgency." Clinical Medicine Insights: Therapeutics 2 (January 2010): CMT.S4606. http://dx.doi.org/10.4137/cmt.s4606.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The overactive bladder (OAB) is a debilitating condition in which patients suffer from urinary urgency, frequency and nocturia with or without urge urinary incontinence. The mainstay of pharmacotherapy for OAB is muscarinic receptor antagonists, which have been shown to be effective treatments for the symptoms of OAB. The mechanism underlying the efficacy of antimuscarinic agents against the symptoms of OAB is not completely understood. This review explores the role of bladder mucosal muscarinic receptors in the signaling pathways that are activated in response to bladder filling. The cholinergic system is seen to be involved in bladder afferent signaling at many levels and as such muscarinic receptor antagonists may affect bladder signaling via numerous pathways including release of mediators from the bladder urothelium and activation of suburothelial myofibroblasts and afferent nerves. Therefore the mucosal cholinergic system may represent another target for the antimuscarinic agents used to treat OAB.

26

Chuang, Po-Heng, Yi-Huei Chang, Po-Jen Hsiao, and Eric Chieh-Lung Chou. "Diagnostic Potential of Low Serum Platelet, Albumin and Prolong PT-INR for Overactive Bladder and Nocturia in Chronic Hepatitis-Related Liver Cirrhosis." Journal of Clinical Medicine 10, no. 13 (June 27, 2021): 2838. http://dx.doi.org/10.3390/jcm10132838.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Overactive bladder (OAB) is defined as urgency, usually with frequency, nocturia, and incontinence. Patients with liver cirrhosis often present with urinary complaints. The possible reason for this is fluid redistribution, which may induce OAB resulting from portal hypertension and ascites. We conducted this study to investigate predictors of OAB in cirrhotic patients. A total of 164 patients with chronic viral hepatitis-related liver cirrhosis were enrolled and 158 (96.3%) completed the Overactive Bladder Symptoms Score (OABSS) questionnaire. Age, severity of liver cirrhosis, comorbidities, serum sodium level, use of diuretics, body mass index and renal function were also recorded. In the study cohort, the prevalence of OAB was 31.01% and the prevalence of urge incontinence (OAB wet) was 18.3%. Patients with an urgency score ≥2 in OABSS had a significantly lower platelet level (p = 0.025) regardless of the use of diuretics. In addition, 98 patients (62%) with nocturia and 29 patients (18%) with urge incontinence had significantly lower levels of serum albumin (p = 0.028 and 0.044, respectively). In conclusion, patients with liver cirrhosis have a high prevalence of overactive bladder. A low platelet and low serum albumin level in these patients may be predictors for overactive bladder. And longer PT-INR is also a possible biomarker for nocturia.

27

Allison, Sara J., and William Gibson. "Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience." Therapeutic Advances in Urology 10, no. 12 (September 26, 2018): 411–19. http://dx.doi.org/10.1177/1756287218801282.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Overactive bladder (OAB), the syndrome characterized by urgency, with or without urgency incontinence, usually with frequency and nocturia, in the absence of infection or other pathology, is a common, distressing and often debilitating condition with a high prevalence in the general population. For many years, the only available pharmacological treatment for OAB were the antimuscarinic agents. More recently, mirabegron, a selective agonist of the β3 adrenergic receptor, has become available. In this article we review the current evidence and experience of its use.

28

Takahashi, Kyo, Tomoki Tanaka, Yasuyo Yoshizawa, Mahiro Fujisaki-Sueda-Sakai, Bo-Kyung Son, and Katsuya Iijima. "Lower urinary tract symptoms and functional ability in older adults: a community-based cross-sectional study." BMJ Open 12, no. 4 (April 2022): e054530. http://dx.doi.org/10.1136/bmjopen-2021-054530.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

ObjectivesFunctional ability, or the ability to live actively in older age, is essential for healthy ageing. This study assessed the association between the five types of lower urinary tract symptoms (LUTS) and functional ability among community-dwelling older adults (≥65 years old).DesignA cross-sectional study.SettingCommunity-dwelling older adults (≥65 years old) randomly selected from the basic resident register of Kashiwa city as part of the Kashiwa study.ParticipantsThe study included 916 community-dwelling older adults (481 male participants) in Japan.Outcome measuresA self-administered questionnaire was used to collect data regarding LUTS, which included frequency, nocturia, urgency, urinary incontinence and overactive bladder (OAB). Functional ability was measured using the Japan Science and Technology Agency Index of Competence. Sex-stratified logistic regression analyses were conducted, adjusting age, obesity, alcohol consumption, polypharmacy and comorbidities.ResultsMale participants experienced symptoms of frequency, nocturia, urgency, urinary incontinence and OAB at rates of 68.0%, 89.0%, 16.0%, 3.7% and 4.3%, respectively. Female participants experienced these symptoms at rates of 68.3%, 80.0%, 11.0%, 7.4% and 8.5%, respectively. Among male participants, lower functional ability was only associated with nocturia (≥3 times/night) (adjusted OR (AOR): 1.71, 95% CI 1.05 to 2.79). Contrarily, lower functional ability among female participants was significantly associated with frequency (AOR: 1.61, 95% CI 1.04 to 2.49), urgency (AOR: 2.06, 95% CI 1.08 to 3.95) and OAB (AOR: 2.43, 95% CI 1.15 to 5.11).ConclusionThe different associations between LUTS and functional ability by sex might be related to differences in the effect of comorbidities and physical fatigue. Our results help clarify the multifaceted effects of LUTS in old age, the need for early detection and treatment of LUTS, and the importance of maintaining functional ability.

29

Cirovic, Dragana, Ivana Petronic, Dejan Nikolic, Radivoj Brdar, Polina Pavicevic, and Tatjana Knezevic. "Effects of electrotherapy in treatment of neurogenic bladder in children with occult spinal dysraphism." Srpski arhiv za celokupno lekarstvo 137, no. 9-10 (2009): 502–5. http://dx.doi.org/10.2298/sarh0910502c.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Introduction Neurogenic bladder can develop as a result of various degrees of neurogenic lesion in spina bifida. The degree of bladder dysfunction depends on the level and type of spina bifida. Due to results upon complete diagnostic protocols, treatment options are applied. Objective Comparison of therapy results of patients with occult spinal dysraphism with neurogenic bladder that under-went medicamentous therapy and medicamentous with electrotherapy treatment. Methods We had 49 patients with neurogenic bladder that were treated at the University Children's Hospital in Belgrade in the period 2003-2008. The first group of children received medicamentous therapy and the second group received medicamentous therapy with transcutaneous electric nerve stimulation. In both groups we evaluated 4 symptoms: daily enuresis, enuresis nocturna, urgency and frequency and 4 urodynamic parameters: lower bladder capacity, unstable contractions and residual urine and detrusor sphincter dyssynergia. Follow-up urodynamic evaluation was done after 3, 6 and 12 months respectively. Results Our findings pointed out a high statistical significance of improvement in all evaluated urodynamic parameters of neurogenic bladder (predominantly in bladder capacity) in the group of children with combined therapy as well in resolution of symptoms (predominantly enuresis nocturna, urgency and frequency). Conclusion Combined therapy is more efficient in treatment of children with neurogenic bladder. Electrotherapy is non-invasive, easily applicable and has had a significant place in treatment of children with dysfunctional voiding.

30

Cunha, Margarida, Mafalda Matias, and Inês Marques. "Ehlers-Danlos syndrome presenting with primary nocturnal enuresis." BMJ Case Reports 13, no. 2 (February 2020): e231977. http://dx.doi.org/10.1136/bcr-2019-231977.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Ehlers-Danlos syndrome (EDS), hypermobility type, is probably the most common EDS type, as well as the most common heritable connective tissue disorder. Bladder dysfunction is a rare clinical manifestation of EDS and manifests itself as primary nocturnal enuresis. We present a 10-year-old boy referred to the paediatrics nephrology consultation due to primary nocturnal enuresis and day time symptoms of urinary urgency. During the appointment, a tendency to joint hypermobility was noted. On evaluation the skin was hyperextensible and the Beighton score was positive. The genetic testing revealed a variant of the COL5A1 gene not yet described in the literature.

31

Deleplanque, P., S. Refray, and B. Levy. "Évaluation des délais et de la pertinence des transfusions nocturnes aux urgences du centre hospitalier de Niort." Transfusion Clinique et Biologique 21, no. 4-5 (November 2014): 269. http://dx.doi.org/10.1016/j.tracli.2014.08.086.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

C., Shakthi, Sritharan B., Muthuveeran M., Manivannan M. R., Justin C., and GanesaPandian D. "Prevalence of non-motor symptoms in Parkinson’s disease." International Journal of Research in Medical Sciences 7, no. 5 (April 26, 2019): 1459. http://dx.doi.org/10.18203/2320-6012.ijrms20191488.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Background: Parkinson’s disease is a common neurodegenerative movement disorder characterised by motor symptoms of rest tremor, bradykinesia, rigidity and postural instability and non-motor symptoms (NMS) which include neuropsychiatric symptoms, sleep disturbances, autonomic symptoms, sensory symptoms and symptoms of mixed aetiology. Parkinson’s Disease Non Motor Group (PD-NMG) devised a comprehensive clinic-based self-completed NMS questionnaire that allows easy identification of NMS by the physician. Most NMS have a poor response to dopaminergic therapy as it is due to dysfunction of the serotonergic and noradrenergic pathways. Treatment of these nonmotor symptoms help in improving the quality of life in patients with Parkinson’s disease.Methods: There were 100 patients with Parkinson’s disease who had presented to our neuromedicine movement clinic were included in the study. Patients were diagnosed as PD based on UK Parkinson’s disease brain bank criteria. The inclusion criteria were diagnosis as PD, age >18 yrs, inclusion of both males and females and consent for the study. Patients with atypical parkinsonism and secondary parkinsonism, stroke, intake of antipsychotics were excluded from the study. Non motor symptom questionnaire was given to the study group and frequency of occurrence of each non motor symptoms and their predominance in both males and females were studied. The frequency of each NMS was calculated by computing the number of yes response and calculating the percentage related to the number of patients in the sample. Analysis was done to calculate the frequency of all NMS among the enrolled patient.Results: Nocturnal sleep disturbances (43%) were most common followed by constipation (29%).The most common non motor symptoms in males were constipation (20%), urinary urgency (18%) and nocturia (11%).The most common non motor symptoms in females were nocturnal sleep disturbance (25%), feeling sad (19%), unexplained pains (17%) and being anxious (13%).Conclusions: Non motor symptom questionnaire helps in screening patients with Parkinson’s disease of non-motor symptoms and aims at providing holistic treatment improving the quality of life.

33

Rakowska-Silska, Magda, Katarzyna Jobs, Aleksandra Paturej, and Bolesław Kalicki. "Voiding Disorders in Pediatrician’s Practice." Clinical Medicine Insights: Pediatrics 14 (January 2020): 117955652097503. http://dx.doi.org/10.1177/1179556520975035.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Voiding disorders result usually from functional disturbance. However, relevant organic diseases must be excluded prior to diagnosis of functional disorders. Additional tests, such as urinalysis or abdominal ultrasound are required. Further diagnostics is necessary in the presence of alarm symptoms, such as secondary nocturnal enuresis, weak or intermittent urine flow, systemic symptoms, glucosuria, proteinuria, leukocyturia, erythrocyturia, skin lesions in the lumbar region, altered sensations in the perineum. Functional micturition disorders were thoroughly described in 2006, and revised in 2015 by ICCS (International Children’s Continence Society) and are divided into storage symptoms (increased and decreased voiding frequency, incontinence, urgency, nocturia), voiding symptoms hesitancy, straining, weak stream, intermittency, dysuria), and symptoms that cannot be assigned to any of the above groups (voiding postponement, holding maneuvers, feeling of incomplete emptying, urinary retention, post micturition dribble, spraying of the urinary stream). Functional voiding disorders are frequently associated with constipation. Bladder and bowel dysfunction (BBD) is diagnosed when lower urinary tract symptoms are accompanied by problems with defecation. Monosymptomatic enuresis is the most common voiding disorder encountered by pediatricians. It is diagnosed in children older than 5 years without any other lower urinary tract symptoms. Other types of voiding disorders such as: non-monosymptomatic enuresis, overactive and underactive bladder, voiding postponement, bladder outlet obstruction, stress or giggle incontinence, urethrovaginal reflux usually require specialized diagnostics and therapy. Treatment of all types of functional voiding disorders is based on non-pharmacological recommendations (urotherapy), and such education should be implemented by primary care pediatricians.

34

Leyva Vazquez, José I., Guadalupe Guerrero Reyes, Adrián Gutiérrez González, Ricardo Hernández Velázquez, Karen M. Loya Maldonado, Omar Treviño Cavazos, Jennifer E. Reyes Alcaraz, Alejandra Robledo Torres, Sara Y. Saca Cuevas, and Juan C. Herrera Morales. "Female pelvic floor myofascial syndrome and its relationship with lower urinary tract storage symptoms." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 13, no. 4 (March 28, 2024): 826–29. http://dx.doi.org/10.18203/2320-1770.ijrcog20240772.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Background: Pelvic floor myofascial syndrome is defined as non-articular skeletal muscle pain, characterized by the presence of trigger points. Present in 14-23% of patients with chronic pelvic pain. It has an impact on urinary function. The prevalence of lower urinary tract symptoms is 15-67%, with storage symptoms predominating in patients with PFMS. Objective was to determine the relationship between female pelvic floor myofascial syndrome and lower urinary tract storage symptoms. Methods: This was a retrospective, observational, descriptive, cross-sectional, homodemic and single-center study at University Hospital Doctor José Eleuterio González, Monterrey, Nuevo Leon, Mexico from period one from April 1st to June 30th, 2022. Type of non-probabilistic convenience sampling. Database in Excel 2016, Pearson's Х² statistical test in the SPSS V25® program. Results: 136 patients with PFMS and LUTS storage were evaluated. The most frequent age group was 46-55 years with 33.1% (N=45); the marital status was married with 74.3% (N=101). In relation to education 55.9% (N=76) with a bachelor's degree. The most frequent storage symptoms were nocturia 67.6% (N=92) p<0.05, frequency 60.3% (N=82) p=0.512, urgency 57.4% p<0.005. Conclusions: Knowing the correlation between PFMS and storage LUTS can guide specific pain treatment with review of urinary symptoms. In patients with nocturia, frequency, urgency, SUI and UUI, a physical examination should be performed and included trigger points in the pelvic floor. Nocturia is the most prevalent storage LUTS in PFMS.

35

Kelleher, CJ, J. Filshie, G. Burton, V. Khullar, and LD Cardozo. "Acupuncture and the Treatment of Irritative Bladder Symptoms." Acupuncture in Medicine 12, no. 1 (May 1994): 9–12. http://dx.doi.org/10.1136/aim.12.1.9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The conventional management of irritative bladder symptoms, namely urgency, urge incontinence, frequency and nocturia, with anticholinergic medication is limited by the side effects of treatment. Acupuncture is shown to be as effective in the management of irritative bladder symptoms as conventional anticholinergic therapy, with few side effects and a high degree of patient acceptability and compliance.

36

Varahabhatla, Vamsi, Juraj Jug, Ingrid Prkačin, and Martina Lovrić Benčić. "MEDICACIÓN, PERFIL DE INMERSIÓN NOCTURNA Y EMERGENCIA HIPERTENSIVA." Revista Cientifica Ciencia Medica 25, no. 1 (September 19, 2022): 35–42. http://dx.doi.org/10.51581/rccm.v25i1.466.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Introducción: El objetivo de este estudio fue analizar la medicación utilizada por los pacientes con crisis hipertensiva (presión arterial superior a 180/120mmHg) y su impacto en los principales factores de riesgo para el desarrollo de la emergencia hipertensiva. Métodos: Un total de 233 pacientes (108 hombres, 125 mujeres), 184 tenían urgencia hipertensiva/ 53 emergencia (54,44% /50,95% en mujeres) en el servicio de Urgencias durante 11 meses. Los pacientes fueron divididos en cinco grupos de edad según décadas a partir de los 40 años (media de 65,85 años) y un total de diez grupos según el tipo de medicación hipertensiva que utilizaban (IECA, ARA, BB, BCC, diuréticos, moxonidina y sus combinaciones). Resultados: Utilizando monoterapia antihipertensiva el porcentaje de urgencias hipertensivas fue del 100,00%, 50,00%, 41,66%, 33,33%, 21,05%. El uso de IECA + BCC + diuréticos disminuyó significativamente el número de urgencias al 0%, 18,47%, 21,05%, 25,00%, 33,33%; pero la adición de betabloqueantes disminuyó el riesgo. En general, 53 pacientes no tenían medicación (22,75%) y 68 de 233 pacientes eran fumadores (29,18%, 63,23% hombres), de los cuales 36 pacientes tuvieron una urgencia hipertensiva (52,94% de los fumadores). El mayor número de hipertensos no inmersivos se encontró en los pacientes que tomaban ARA, diuréticos y/o BCC, pero el menor número se mostró en los pacientes que tomaban IECA en combinación con moxonidina (-20,07%). El 22,02% de los fumadores no eran hipertensos inmersivos (-54,67% de los no fumadores). El odds ratio para obtener una emergencia hipertensiva en caso de que el paciente tuviera un perfil no inmersivo fue de 4,18 (IC 1,02 - 18,89, p < 0,05). Los pacientes que tomaban una medicación diferente (o ninguna) no tenían mayor probabilidad de desarrollar una emergencia hipertensiva (OR 1,21, p = NS). No se encontraron diferencias en la incidencia de perfil no inmersivo entre géneros (72,12% varones, 72,83% mujeres). Conclusión: Las combinaciones de toda la medicación antihipertensiva mostraron beneficios sobre la monoterapia. Una mayor presión arterial de 24 horas y nocturna (perfil de hipertensión no inmersiva) se asoció significativamente con un mayor cambio para desarrollar una emergencia hipertensiva.

37

Mody, Rutvi Manoj, Yogita M. Bhargude, and Kailash M. Kothari. "A Case of Refractory Intractable Bladder Pain Syndrome Treated with Superior Hypogastric Nerve Chemical Neurolysis." Indian Journal of Pain 37, no. 3 (2023): 184–86. http://dx.doi.org/10.4103/ijpn.ijpn_98_22.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Bladder pain syndrome (BPS) is a severely debilitating condition. BPS is a symptom complex affecting the urinary bladder, which is characterized by pelvic pain, urinary urgency, frequency, and nocturia. In this case report, we have presented a patient with BPS who was not responsive to conventional treatment and was managed successfully by diagnostic superior hypogastric plexus block followed by alcohol neurolysis.

38

Yi, Junseok, Seong Jin Jeong, Min Soo Chung, Hongzoo Park, Sang Wook Lee, Seung Hwan Doo, Cheol Yong Yoon, Sung Kyu Hong, Seok-Soo Byun, and Sang Eun Lee. "Efficacy and tolerability of combined medication of two different antimuscarinics for treatment of adults with idiopathic overactive bladder in whom a single agent antimuscarinic therapy failed." Canadian Urological Association Journal 7, no. 1-2 (February 20, 2013): 88. http://dx.doi.org/10.5489/cuaj.269.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Objective: Recent studies have investigated a combination of two antimuscarinics for adult neurogenic bladder managed with clean intermittent catheterization or pediatric refractory overactive bladder (OAB). We assessed the efficacy and tolerability of this strategy in adults with idiopathic OAB.Methods: We reviewed 49 patients with idiopathic OAB whoreceived combined antimuscarinic medication. Patients had seriallyreceived different kinds of antimuscarinics as monotherapy, but wished to take combined medication due to a lack of sufficient subjective improvement in urgency, even with dosage escalation. Efficacy was measured by changes of episodes of urgency, daytime voiding, nocturia and mean voided volume before and after the addition of the second antimuscarinic.Results: The mean duration of combined medication was 9.3 months. After adding the second antimuscarinic, urgency per day decreased from 3.8 to 1.9 (p < 0.001) and daytime voiding decreased from 10.4 to 7.4 (p < 0.001). The number of nocturia episodes and the mean voided volume also improved, although therewas no statistical significance. Efficacy did not differ between the 29 cases, with non-selective and non-selective drugs and 20 cases with non-selective and M3 selective drugs. Thirty-three (67.3%) patients reported to have benefited from combined medication. Maximal flow rate and post-void residual volume did not change in either of the sexes. Eleven (22.4%) patients discontinued the combination due to continued ineffectiveness and dry mouth.Conclusion: This retrospective study suggests that combined medication can help adults with refractory idiopathic OAB. Combined medication was tolerated in most of our patients.

39

Arruda, Raquel, Claudia Takano, Manoel Girão, Jorge Haddad, Gabriel Aleixo, and Rodrigo Castro. "Treatment of Non-neurogenic Overactive Bladder with OnabotulinumtoxinA: Systematic Review and Meta-analysis of Prospective, Randomized, Placebo-controlled Clinical Trials." Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics 40, no. 04 (April 2018): 225–31. http://dx.doi.org/10.1055/s-0038-1642631.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

AbstractWe performed a systematic review and meta-analysis of randomized placebo-controlled trials that studied non-neurogenic overactive bladder patients who were treated with 100 units of onabotulinumtoxinA or placebo. The primary purpose of our study was to evaluate the clinical effectiveness with regard to urinary urgency, urinary frequency, nocturia, and incontinence episodes. Our secondary purpose consisted of evaluating the adverse effects. Our initial search yielded 532 entries. Of these, seven studies met all the inclusion criteria (prospective, randomized, placebo-controlled studies, ≥ 3 points on the Jadad scale) and were selected for analysis. For all primary endpoints, the toxin was more effective than placebo (p < 0.0001; 95% confidence interval [95CI]), namely: urgency (mean difference = -2.07; 95CI = [-2.55–1.58]), voiding frequency (mean difference = -1.64; 95CI = [-2.10–1.18]), nocturia (mean difference = -0.25; 95CI = [-0.39–0.11]) and incontinence episodes (mean difference = -2.06; 95CI= [-2.60–1.52]). The need for intermittent catheterization and the occurrence of urinary tract infection (UTI) were more frequent in patients treated with onabotulinumtoxinA than in patients treated with placebo (p < 0.0001). Compared with placebo, onabotulinumtoxinA had significantly and clinically relevant reductions in overactive bladder symptoms and is associated with higher incidence of intermittent catheterization and UTI.

40

Wiatr, Tomasz, and Piotr Chłosta. "Safety and efficacy of mirabegron and solifenacin in elderly patient with overactive bladder." Medycyna Faktów 14, no. 1 (March 31, 2021): 53–57. http://dx.doi.org/10.24292/01.mf.0121.6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Lower urinary tract symptoms, including urgency, urgency incontinence, pollakiuria and nocturia are common in the elderly people and has significant impact on quality of life. Pharmacological treatment is recommended when conservative management, such as fluid intake normalization or bladder training, does not alleviate symptoms. Antimuscarinics were often used as the I line treatment for OAB, as these drugs block the activity of the muscarinic M2/M3 receptors in the bladder and provide a significant clinical benefit for OAB symptoms in the elderly people, but their side effects are common, often leading to treatment discontinuation. Mirabegron, a β3-adrenoceptor agonist, shows similar efficacy to antimuscarinic drugs without the risk of anticholinergic effects.

41

Tikkinen, Kari A. O., Anssi Auvinen, Aila Tiitinen, Antti Valpas, Theodore M. Johnson, and Teuvo L. J. Tammela. "Reproductive factors associated with nocturia and urinary urgency in women: a population-based study in Finland." American Journal of Obstetrics and Gynecology 199, no. 2 (August 2008): 153.e1–153.e12. http://dx.doi.org/10.1016/j.ajog.2008.03.054.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Wiatr, Tomasz, and Piotr Chłosta. "Long-term clinical use of mirabegron in patients with overactive bladder syndrome." Medycyna Faktów 13, no. 4 (December 31, 2020): 460–64. http://dx.doi.org/10.24292/01.mf.0420.12.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Overactive bladder syndrome (OAB) is defined by the International Continence Society (ICS) as urinary urgency with increased daytime frequency and nocturia in the absence of proven infection or any other pathology, usually with or without urgency incontinence. Pharmacotherapy with antimuscarinic drugs is highly effective, but more than 60% of patients discontinue the treatment. Development of mirabegron, a β3-adrenoceptor agonist (β3-AR), has become an expected pharmacotherapy option for the non-invasive treatment of overactive bladder. The available studies show that long-term treatment with 50 mg mirabegron in patients with OAB is associated with reducing the severity of symptoms. Data from clinical trials show that mirabegron provides efficacy similar to antimuscarinic drugs, but with a better tolerance profile.

43

Palma, Thais, Raimondi Marina, Souto Sophia, Fozzatti Celina, Palma Paulo, and Riccetto Cassio. "Correlation between body mass index and overactive bladder symptoms in pre-menopausal women." Revista da Associação Médica Brasileira 60, no. 2 (2014): 111–17. http://dx.doi.org/10.1590/1806-9282.60.02.007.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Objective: The aim of the study was to establish a correlation between Overactive Bladder (OAB) symptoms and Body Mass Index (BMI) in women aged 20-45. Methods: We interviewed 1.050 women aged 20-45 in the area of Campinas, Brazil, to investigate the prevalence of overactive bladder symptoms. In this study, we used the ICIQ-OAB questionnaire (ICS standard), in its validated portuguese version and a specific questionnaire for the demographics, which includes information about BMI. Results: Overall, women with BMI ≥30 presented a significantly higher score than women with a lower BMI (18.5 - 24.9) (p=0.0066). In the analysis of individual symptoms, no significant differences were found regarding urinary frequency (p=0.5469). Women with BMI ≥30 presented more nocturia than women with BMI ranging between 18.5 and 24.9 (p=0.0154). Women in the group of BMI 25 - 29.9 presented more urgency than women with BMI 18.5 - 24.9 (p=0.0278). Significant difference was also found regarding urge-incontinence; women with BMI 25 - 29.9 presented a higher score than women in the group 18.5 - 24.9 (p= 0.0017). Analysis was also performed on the visual analogue scale regarding how much each symptom bothers the women (quality of life). There were no significant differences regarding frequency, nocturia or urgency but urgency incontinence bother was significant. Women with BMI 25 - 29.9 were more bothered by incontinence than women with BMI 18.5 - 24.9 (p=0.002). Conclusion: In conclusion, this study reinforces the correlation between BMI and OAB symptoms. Obese women present more OAB symptoms than non-obese women.

44

Daucher, MD, MS, James A., Anjali P. Patel DO, MPH, and Estee George PhD. "The peripheral nerve evaluation: determining which symptoms lead to a successful test." Obstetrics & Gynecology International Journal 14, no. 1 (February 23, 2023): 26–29. http://dx.doi.org/10.15406/ogij.2023.14.00688.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Objective: To identify the symptom or set of symptoms most improved in patients undergoing a successful peripheral nerve evaluation (PNE) for refractory overactive bladder syndrome (OAB). Methods: An analysis was conducted on refractory OAB patients to determine which symptom (nocturia, daytime voids, urgency, leaks per day, pad use per day and time to reach the bathroom) most improved following a PNE. This was measured in two ways: 1) by patient responses to a questionnaire and 2) by determining changes in symptoms with use of a voiding diary. Patients completed a pre- and post-questionnaire by phone interview. Descriptive statistics were used to analyze demographic and baseline characteristics as well as responses to questionnaires. Changes in voiding patterns were analyzed using a paired-samples t-test. Results: Overall, 28 patients were included. Prior to their evaluation patients indicated they were most bothered by urgency (n=26, 92.8%), followed by number of leaks per 24 hours (n = 24, 85.7%). After their evaluation, symptom improvement was highest for number of voids at night (n = 20, 71.4%) followed by sense of urgency (n = 18, 64.3%). Paired-samples t-tests on pre- and post-PNE voiding diaries revealed significant improvements in number of daytime voids (p = 0.015), number of leaks per 24 hours (p = 0.001), and number of urges per 24 hours (p = 0.001). Conclusion: Voiding diaries alone cannot be used to accurately determine symptom improvement. Clinicians must take into account the degree to which their patients are bothered by their symptoms. In an elderly population, improvement in nocturia has important implications including decreased morbidity.

45

Govier, Fred E., Neila Smith, and Takeshi Uchida. "Efficacy and Safety of 10 mg Solifenacin Succinate in Patients with Overactive Bladder Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Pivotal Trial." Clinical Medicine Insights: Urology 4 (January 2010): CMU.S4960. http://dx.doi.org/10.4137/cmu.s4960.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Introduction This multicenter, randomized, double-blind, parallel-group, Phase III, pivotal trial investigated the efficacy and safety of solifenacin succinate 10 mg, a once-daily (OD) oral antimuscarinic agent, in overactive bladder syndrome (OAB). Materials and methods A total of 634 adult patients with OAB symptoms were randomized to either solifenacin 10 mg (n = 318) or placebo (n = 316) OD over 12 weeks, to examine changes from baseline in micturition-, incontinence-, urgency- and nocturia-episodes/24 hours, measured using a 3-day diary. Results Solifenacin significantly reduced the mean number of micturition-, urgency- and incontinence-episodes/24 hours at end of treatment ( P < 0.001 for all versus placebo); these improvements were observed at 4 weeks, and continued over 12 weeks. Adverse events were generally mild or moderate in severity and typically anticholinergic in nature. Conclusions Solifenacin 10 mg OD was well tolerated and effective in treating major OAB symptoms, including urinary incontinence, frequency and urgency.

46

Astuti, Vitaria Wahyu, Ayu Ratantri, and Sandy Kurniajati. "Literature Review: Quality of Life in Patients with Overactive Bladder." Jurnal Ners dan Kebidanan (Journal of Ners and Midwifery) 9, no. 1 (April 15, 2022): 127–34. http://dx.doi.org/10.26699/jnk.v9i1.art.p127-134.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Overactive Bladder, hereinafter referred to as OAB, is a complaint of urgency accompanied by urgency incontinence or without urgency incontinence, which is usually followed by an increase in urinary frequency during the day and nocturia, without infection or other pathology of the bladder. OAB can affect the quality of life of sufferers. This study analyzes the relationship between OAB and quality of life based on databases such as Science Direct, Elsevier, Willey Library, Sage Journal, and Google Scholar, 2010-2020. The study results show that the prevalence of OAB in men and women increases with age and women are at greater risk major have OAB. The incidence of OAB is most experienced at the age of > 60 years. Based on 10 journals, 6 journals stated that there was a relationship between OAB and quality of life. The conclusion of this study is that OAB can reduce the quality of life in men and women

47

Araklitis, George, Georgina Baines, Ana Sofia da Silva, Dudley Robinson, and Linda Cardozo. "Recent advances in managing overactive bladder." F1000Research 9 (September 11, 2020): 1125. http://dx.doi.org/10.12688/f1000research.26607.1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Overactive bladder syndrome (OAB) is defined as urinary urgency, usually accompanied by frequency and nocturia, with or without urgency incontinence, in the absence of urinary tract infection or other obvious pathology. In this review, we focus on recent advances in the management of OAB. We examine the evidence on the effect of anticholinergic load on OAB patients. Advances in medical treatment include a new beta-3 agonist, vibegron, which is thought to have fewer drug interactions than mirabegron. Treatment of genitourinary syndrome of the menopause with oestrogens and ospemifene have also shown promise for OAB. Botulinum toxin has been shown to be an effective treatment option. We discuss the new implantable neuromodulators that are on the market as well as selective bladder denervation and laser technology.

48

Fang-Liu, Gu, Reng Zong-Ying, Shang Gang-Zhi, Shao Hong-Xun, Wang Beng, Cheng Zeng-De, Jiang Yu, et al. "Treatment of Urgency and Urge Incontinence with Flavoxate in the People's Republic of China." Journal of International Medical Research 15, no. 5 (September 1987): 312–18. http://dx.doi.org/10.1177/030006058701500507.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Flavoxate is a smooth muscle relaxant widely used to treat urgency and urge incontinence. It has been used in an unblinded, uncontrolled clinical trial in 14 urology departments in universities and major hospitals in the People's Republic of China involving 361 patients with urgency/incontinence of various types. Patients were given 200 mg three times daily, orally, for 2 weeks, although 33 patients received a daily dosage of 1200 mg. Frequency, urgency, dysuria, nocturia and incontinence were assessed and scored clinically prior to and after treatment. Three departments also included urodynamic investigations, e.g. monitoring of the end-residual volume. Results from 336 evaluable patients indicate that 228 (67%) were completely cured of urgency/incontinence symptoms, 66 (20%) were improved and 42 (13%) patients were unchanged. Flavoxate was also effective in 77.4% of patients refractory to previous anti-cholinergic treatment. Treatment did not increase the end-residual volume and adverse events occurred only in four (1.3%) patients, two (0.6%) of which discontinued the therapy. The 1200 mg dose produced a complete cure in 82% of patients and improvement in the remaining 18%, with no side-effects. In conclusion, flavoxate is an effective and well tolerated treatment for urgency/incontinence of various causes.

49

Kaditis, Athanasios G., Frederic Dallaire, and Jean-Paul Praud. "Nocturnal oximetry in pediatric respiratory disease: Urgent need for developing standardized interpretation rules." Pediatric Pulmonology 53, no. 8 (March 6, 2018): 1001–3. http://dx.doi.org/10.1002/ppul.23970.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Vishwajit, Sonia, and Karl-Erik Andersson. "Terminology of Lower Urinary Tract Symptoms. Helpful or Confusing ?" Scientific World JOURNAL 9 (2009): 17–22. http://dx.doi.org/10.1100/tsw.2009.9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

An established standardized terminology is necessary for communication of scientific information, and for prevention of mistreatment and misdiagnosis. Terminology concerning the lower urinary tract has been much discussed; in particular, the meaning of terms like lower urinary tract symptoms (LUTS), urgency, frequency and nocturia, overactive bladder (OAB), and detrusor overactivity (DO). It is natural and desirable that all suggested definitions are subject to criticism, and it is important that discussions for improvement of the existing terminology continue.

Статті в журналах з теми "Urgence nocturne"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями